Notification of Drug Policy Revisions Effective April 1, 2023 (Posted December 30, 2022)
| Medical Drug Policy Name | Revised Criteria |
| Gonadotropin Releasing Hormone Therapy “Notification” |
Original medical policy criteria issued. Policy notification given 12/30/2022 for effective date 4/1/2023. |
| Spesolimab-sbzo (Spevigo®) “Notification” |
Original medical policy criteria issued. Policy notification given 12/30/2022 for effective date 4/1/2023. |
Blue Connect